Heavily relapsed refractory multiple myeloma (MM) remains a challenge in terms of treatment. Joseph Mikhael, MD, from the Mayo Clinic, Phoenix, AZ, USA, talks to us about the potential of administering venetoclax, a Bcl2 inhibitor, to treat MM patients with t(11;14) and the promising results obtained from clinical studies, namely an improved and prolonged response rate and high tolerance. He also describes the need to explore this regimen in combination with bortezomib, with the aim of potentially overcoming bortezomib resistance in MM (NCT02755597) and ends with a positive note, stating that single-agent venetoclax may be a viable option for treating MM with t(11;14). This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.